Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir
Patricia A Escobar, Zhanna Sobol, Randy R Miller, Sandrine Ferry-Martin, Angela Stermer, Binod Jacob, Nagaraja Muniappa, Rosa Sanchez, Kerry T Blanchard, Alema Galijatovic- Idrizbegovic, Rupesh P Amin, Sean P Troth
doi:10.1093/toxsci/kfae112/7762651
Molnupiravir is registered or authorized in several countries as a 5-day oral COVID-19 treatment for adults. Molnupiravir is a prodrug of the antiviral ribonucleoside β-D-N4-hydroxycytidine (NHC) that distributes into cells, where it is phosphorylated to its pharmacologically active ribonucleoside triphosphate (NHC-TP) form. NHC-TP incorporates into SARS-CoV-2 RNA by the viral RNA-dependent RNA polymerase, resulting in an accumulation of errors in the viral genome, leading to inhibition of viral replication and loss of infectivity. The potential of molnupiravir to induce genomic mutations and DNA damage was comprehensively assessed in several in vitro and in vivo genotoxicity assays and a carcinogenicity study, in accordance with international guideline recommendations and expert opinion. Molnupiravir and NHC induced mutations in vitro in bacteria and mammalian cells but did not induce chromosome damage in in vitro or in vivo assays. The in vivo mutagenic and carcinogenic potential of molnupiravir was tested in a series of in vivo mutagenicity studies in somatic and germ cells (Pig-a Assay and Big Blue TGR Mutation Assay) and in a carcinogenicity study (transgenic rasH2-Tg mouse), using durations of exposure and doses exceeding those used in clinical therapy. In vitro genotoxicity results are superseded by robustly conducted in vivo studies. Molnupiravir did not increase mutations in somatic or germ cells in the in vivo animal studies and was negative in the carcinogenicity study. The interpretation criteria for each study followed established regulatory guidelines. Taken together, these data indicate that molnupiravir use does not present a genotoxicity or carcinogenicity risk for patients.
Conflicts of Interest
References
Bajema, Berry, Streja, Rajeevan, Li et al., Effectiveness of COVID-19 treatment with nirmatrelvirritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with onemonth and six-month outcomes, Ann Intern Med
Bernal, Gomes Da Silva, Musungaie, Kovalchuk, Gonzalez et al., Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients, N Engl J Med
Brandsma, Derr, Zhang, Moelijker, Hendriks et al., Genotoxicity assessment of potentially mutagenic nucleoside analogues using ToxTracker®, Toxicol Lett
De Serres, Brockman, Comparison of the spectra of genetic damage in N4hydroxycytidine-induced ad-3 mutations between nucleotide excision repair-proficient and -deficient heterokaryons of Neurospora crassa, Mutat Res
Dertinger, Phonethepswath, Weller, Nicolette, Murray et al., International Pig-a Gene Mutation Assay Trial: Evaluation of Transferability Across 14 Laboratories, Environ Mol Mutagen
Eastmond, Hartwig, Anderson, Anwar, Cimino et al., Mutagenicity testing for chemical risk assessment: Update of the WHO/IPCS Harmonized Scheme, Mutagenesis
Gollapudi, Lynch, Heflich, Dertinger, Dobrovolsky et al., The in vivo Pig-a assay: A report of the International Workshop on Genotoxicity Testing (IWGT) workgroup, Mutat Res Genet Toxicol Environ Mutagen
Hernandez-Santiago, Beltran, Stuyver, Chu, Schinazi, Metabolism of the anti-hepatitis C virus nucleoside beta-d-N4-hydroxycytidine in different liver cells, Antimicrob Agents Chemother
Hisada, Tsubota, Inoue, Yamada, Ikeda et al., Survey of tumorigenic sensitivity in 6-month rasH2-Tg mice studies compared with 2-year rodent assays, J Toxicol Pathol
Holden, Comparison of somatic and germ cell models for cytogenetic screening, J. Appl. Toxicol
Janion, Glickman, N4-hydroxycytidine: A mutagen specific for at to gc transitions, Mutat Res
Kabinger, Stiller, Schmitzová, Dienemann, Kokic et al., Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis, Nat Struct Mol Biol
Kobayashi, Mori, Ahmed, Hirao, Kato et al., Oxidative DNA damage by N4-hydroxycytidine, a metabolite of the SARS-CoV-2 antiviral molnupiravir, J Infect Dis
Lambert, Singer, Boucher, Douglas, Detailed review of transgenic rodent mutation assays, Mutat Res
Lane, Fan, Regulation of mammalian nucleotide metabolism and biosynthesis, Nucleic Acids Res
Miller, Mcgrath, Zorn, Ekins, Wright et al., Remdesivir and EIDD-1931 interact with human equilibrative nucleoside transporters 1 and 2: Implications for reaching SARS-CoV-2 viral sanctuary sites, Mol Pharmacol
Miranda, Mckinzie, Dobrovolsky, Revollo, Evaluation of the mutagenic effects of molnupiravir and N4-hydroxycytidine in bacterial and mammalian cells by HiFi sequencing, Environ Mol Mutagen
Morton, Alden, Roth, Usui, The Tg rasH2 mouse in cancer hazard identification, Toxicol Pathol
Nambiar, Turnquist, Morton, Spontaneous tumor incidence in rasH2 mice:review of internal data and published literature, Toxicol Pathol
Negishi, Tamanoi, Ishii, Kawakami, Yamashita et al., Mutagenic nucleoside analog N4-aminocytidine: Metabolism, incorporation into DNA, and mutagenesis in Escherichia coli, J Bacteriol
O'brien, Beal, Gingerich, Soper, Douglas et al., Transgenic rodent assay for quantifying male germ cell mutant frequency, J Vis Exp
Paranjpe, Belich, Mann, Mckeon, Elbekai et al., A comparison of spontaneous tumors in Tg.rasH2 mice in 26-week carcinogenicity studies conducted at a single test facility during 2004 to 2012 and 2013 to 2018, Toxicol Pathol
Paranjpe, Elbekaei, Shah, Hickman, Wenk et al., Historical control data of spontaneous tumors in transgenic CByB6F1-Tg(HRAS)2Jic (Tg.rasH2) mice, Int J Toxicol
Robison, Heflich, Manjanatha, Elespuru, Atrakchi et al., Appropriate in vivo follow-up assays to an in vitro bacterial reverse mutation (Ames) test positive investigational drug candidate (active pharmaceutical ingredient), drug-related metabolite, or drug-related impurity, Mutat Res Genet Toxicol Environ Mutagen
Salganik, Vasjunina, Poslovina, Andreeva, Mutagenic action of N4hydroxycytidine on Escherichia coli B cyt, Mutat Res
San, Gudi, Wagner, Young, Jacobseon-Kram, Genetic Toxicology
Sheahan, Sims, Zhou, Graham, Pruijssers et al., An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice, Sci Transl Med
Smith, Archer, Forster, Lambert, Rees et al., Analysis of gene mutations and clastogenicity following short-term treatment with azathioprine in MutaMouse, Environ Mol Mutagen
Sobol, Homiski, Dickinson, Spellman, Li et al., Development and validation of an in vitro micronucleus assay platform in TK6 cells, Mutat Res
Strizki, Grobler, Murgolo, Fridman, Johnson et al., Virologic outcomes with molnupiravir in non-hospitalized adult patients with COVID-19 from the randomized, placebo-controlled MOVe-OUT trial, Infect Dis Ther
Suter, Plappert-Helbig, Glowienke, Poetter-Locher, Staedtler et al., Induction of gene mutations by 5-(2-chloroethyl)-2'-deoxyuridine (CEDU), an antiviral pyrimidine nucleoside analogue, Mutat Res
Toots, Yoon, Cox, Hart, Sticher et al., Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia, Sci Transl Med
Troth, Butterton, Deanda, Escobar, Grobler et al., Letter to the editor in response to Zhou et al, J Infect Dis
Van Heer, Majumdar, Parta, Martinie, Dawson et al., Effectiveness of community-based oral antiviral treatments against severe COVID-19 outcomes in people 70 years and over in Victoria, Australia, 2022: an observational study, Lancet Reg Health West Pac
Wai, Chan, Cheung, Wang, Chan et al., Association of molnupiravir and nirmatrelvir-ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19, Lancet Reg Health West Pac
Waters, Stack, Jackson, Bridges, Adler, The performance of short-term tests in identifying potential germ cell mutagens: a qualitative and quantitative analysis, Mutat Res
Williams, Lujan, Kunkel, Processing ribonucleotides incorporated during eukaryotic DNA replication, Nat Rev Mol Cell Biol
Wong, Au, Lau, Lau, Cowling et al., Realworld effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and inhospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the Omicron wave in Hong Kong: an observational study, Lancet
Xie, Bowe, Al-Aly, Molnupiravir and risk of hospital admission or death in adults with Covid-19: emulation of a randomized target trial using electronic health records, BMJ
Xu, Flensburg, Bilardi, Majewski, Uridine-cytidine kinase 2 potentiates the mutagenic influence of the antiviral β-d-N4-hydroxycytidine, Nucleic Acids Res
Yauk, Aardema, Jv, Bishop, Dearfield et al., Approaches for identifying germ cell mutagens: Report of the 2013 IWGT workshop on germ cell assays, Mutation Research
Zeller, Pfuhler, Albertini, Bringezu, Czich et al., A critical appraisal of the sensitivity of in vivo genotoxicity assays in detecting human carcinogens, Mutagenesis
Zhou, Hill, Sarkar, Tse, Woodburn et al., Β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells, J Infect Dis
DOI record:
{
"DOI": "10.1093/toxsci/kfae112",
"ISSN": [
"1096-6080",
"1096-0929"
],
"URL": "http://dx.doi.org/10.1093/toxsci/kfae112",
"abstract": "<jats:title>Abstract</jats:title>\n <jats:p>Molnupiravir is registered or authorized in several countries as a 5-day oral COVID-19 treatment for adults. Molnupiravir is a prodrug of the antiviral ribonucleoside β-D-N4-hydroxycytidine (NHC) that distributes into cells, where it is phosphorylated to its pharmacologically active ribonucleoside triphosphate (NHC-TP) form. NHC-TP incorporates into SARS-CoV-2 RNA by the viral RNA-dependent RNA polymerase, resulting in an accumulation of errors in the viral genome, leading to inhibition of viral replication and loss of infectivity. The potential of molnupiravir to induce genomic mutations and DNA damage was comprehensively assessed in several in vitro and in vivo genotoxicity assays and a carcinogenicity study, in accordance with international guideline recommendations and expert opinion. Molnupiravir and NHC induced mutations in vitro in bacteria and mammalian cells but did not induce chromosome damage in in vitro or in vivo assays. The in vivo mutagenic and carcinogenic potential of molnupiravir was tested in a series of in vivo mutagenicity studies in somatic and germ cells (Pig-a Assay and Big Blue® TGR Mutation Assay) and in a carcinogenicity study (transgenic rasH2-Tg mouse), using durations of exposure and doses exceeding those used in clinical therapy. In vitro genotoxicity results are superseded by robustly conducted in vivo studies. Molnupiravir did not increase mutations in somatic or germ cells in the in vivo animal studies and was negative in the carcinogenicity study. The interpretation criteria for each study followed established regulatory guidelines. Taken together, these data indicate that molnupiravir use does not present a genotoxicity or carcinogenicity risk for patients.</jats:p>",
"author": [
{
"ORCID": "http://orcid.org/0000-0001-9703-6330",
"affiliation": [
{
"name": "Merck & Co. Inc Nonclinical Drug Safety and Pharmacokinetics Dynamics Metabolism and Bioanalysis, Preclinical Development, , Rahway, New Jersey, USA"
}
],
"authenticated-orcid": false,
"family": "Escobar",
"given": "Patricia A",
"sequence": "first"
},
{
"affiliation": [
{
"name": "Merck & Co. Inc Nonclinical Drug Safety and Pharmacokinetics Dynamics Metabolism and Bioanalysis, Preclinical Development, , Rahway, New Jersey, USA"
}
],
"family": "Sobol",
"given": "Zhanna",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Merck & Co. Inc Nonclinical Drug Safety and Pharmacokinetics Dynamics Metabolism and Bioanalysis, Preclinical Development, , Rahway, New Jersey, USA"
}
],
"family": "Miller",
"given": "Randy R",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Merck & Co. Inc Nonclinical Drug Safety and Pharmacokinetics Dynamics Metabolism and Bioanalysis, Preclinical Development, , Rahway, New Jersey, USA"
}
],
"family": "Ferry-Martin",
"given": "Sandrine",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Merck & Co. Inc Nonclinical Drug Safety and Pharmacokinetics Dynamics Metabolism and Bioanalysis, Preclinical Development, , Rahway, New Jersey, USA"
}
],
"family": "Stermer",
"given": "Angela",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Merck & Co. Inc Nonclinical Drug Safety and Pharmacokinetics Dynamics Metabolism and Bioanalysis, Preclinical Development, , Rahway, New Jersey, USA"
}
],
"family": "Jacob",
"given": "Binod",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Merck & Co. Inc Nonclinical Drug Safety and Pharmacokinetics Dynamics Metabolism and Bioanalysis, Preclinical Development, , Rahway, New Jersey, USA"
}
],
"family": "Muniappa",
"given": "Nagaraja",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Merck & Co. Inc Nonclinical Drug Safety and Pharmacokinetics Dynamics Metabolism and Bioanalysis, Preclinical Development, , Rahway, New Jersey, USA"
}
],
"family": "Sanchez",
"given": "Rosa",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Merck & Co. Inc Nonclinical Drug Safety and Pharmacokinetics Dynamics Metabolism and Bioanalysis, Preclinical Development, , Rahway, New Jersey, USA"
}
],
"family": "Blanchard",
"given": "Kerry T",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Merck & Co. Inc Nonclinical Drug Safety and Pharmacokinetics Dynamics Metabolism and Bioanalysis, Preclinical Development, , Rahway, New Jersey, USA"
}
],
"family": "Galijatovic-Idrizbegovic",
"given": "Alema",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Merck & Co. Inc Nonclinical Drug Safety and Pharmacokinetics Dynamics Metabolism and Bioanalysis, Preclinical Development, , Rahway, New Jersey, USA"
}
],
"family": "Amin",
"given": "Rupesh P",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Merck & Co. Inc Nonclinical Drug Safety and Pharmacokinetics Dynamics Metabolism and Bioanalysis, Preclinical Development, , Rahway, New Jersey, USA"
}
],
"family": "Troth",
"given": "Sean P",
"sequence": "additional"
}
],
"container-title": "Toxicological Sciences",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2024,
9,
20
]
],
"date-time": "2024-09-20T15:57:31Z",
"timestamp": 1726847851000
},
"deposited": {
"date-parts": [
[
2024,
9,
20
]
],
"date-time": "2024-09-20T15:57:32Z",
"timestamp": 1726847852000
},
"indexed": {
"date-parts": [
[
2024,
9,
21
]
],
"date-time": "2024-09-21T04:28:10Z",
"timestamp": 1726892890921
},
"is-referenced-by-count": 0,
"issued": {
"date-parts": [
[
2024,
9,
20
]
]
},
"language": "en",
"license": [
{
"URL": "https://creativecommons.org/licenses/by/4.0/",
"content-version": "am",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2024,
9,
20
]
],
"date-time": "2024-09-20T00:00:00Z",
"timestamp": 1726790400000
}
}
],
"link": [
{
"URL": "https://academic.oup.com/toxsci/advance-article-pdf/doi/10.1093/toxsci/kfae112/59212782/kfae112.pdf",
"content-type": "application/pdf",
"content-version": "am",
"intended-application": "syndication"
},
{
"URL": "https://academic.oup.com/toxsci/advance-article-pdf/doi/10.1093/toxsci/kfae112/59212782/kfae112.pdf",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "286",
"original-title": [],
"prefix": "10.1093",
"published": {
"date-parts": [
[
2024,
9,
20
]
]
},
"published-online": {
"date-parts": [
[
2024,
9,
20
]
]
},
"publisher": "Oxford University Press (OUP)",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "https://academic.oup.com/toxsci/advance-article/doi/10.1093/toxsci/kfae112/7762651"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir",
"type": "journal-article"
}
